Skip to main content

Advertisement

Fig. 2 | Cardiovascular Diabetology

Fig. 2

From: Comparative outcomes of heart failure among existent classes of anti-diabetic agents: a network meta-analysis of 171,253 participants from 91 randomized controlled trials

Fig. 2

Ranking of anti-diabetic agents ordered by their respective probability to be the best treatment for heart failure endpoints. SGLT2i sodium-glucoseco-transporter 2 inhibitors, GLP1ra glucagon-like peptide-1 receptor agonists, DPP4i dipeptidyl peptidase 4 inhibitors, TZD thiazolidinediones, MET metformin, SU sulfonylureas, INS insulin, PLA placebo

Back to article page